21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Concomitant Transthyretin Amyloidosis and Severe Aortic Stenosis in Elderly Indian Population : A Pilot Study

      research-article
      , MD, DM a , , MD, DM a , , MD, MMSc b , , MD, MPh c , , MD, DM a , , MD d , , MD, DM a , , MD, DM a , e , , MD, DM, MSc a , , MD, DM a , , MS, MCh f , , MS, MCh f , , MS, MCh f , , MS, MCh f , , MS, MCh f , , MD g , , MD h , , MD h , , MD, DM a ,
      JACC: CardioOncology
      Elsevier
      dual aortic stenosis transthyretin cardiac amyloidosis, severe aortic stenosis, transthyretin cardiac amyloidosis, 99m-technetium pyrophosphate scan, 99mTc-PYP, 99m-technetium pyrophosphate, AS, aortic stenosis, AL-CA, light chain cardiac amyloidosis, ATTR-CA, transthyretin cardiac amyloidosis, EMB, endomyocardial biopsy, GLS, global longitudinal strain, IHC, immunohistochemistry, LfLg AS, low-flow, low-gradient aortic stenosis, SAVR, surgical aortic valve replacement, TAVR, transcatheter aortic valve replacement, TTR, transthyretin

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Prevalence of both degenerative severe aortic stenosis (AS) and transthyretin cardiac amyloidosis (ATTR-CA) increases with age. Dual disease (AS+myocardial ATTR-CA) occurs in significant proportion of patients undergoing surgical aortic valve replacement (SAVR).

          Objectives

          This study aimed to determine the prevalence of ATTR-CA in severe AS in the Indian population, identify noninvasive predictors of its diagnosis, and understand its impact on prognosis.

          Methods

          Symptomatic severe AS patients aged ≥65 years undergoing SAVR were enrolled. ATTR-CA diagnosis was based on preoperative 99m-technetium pyrophosphate (PYP) scan and intraoperatively obtained basal interventricular septum biopsy for myocardial ATTR-CA, and excised native aortic valve for isolated valvular ATTR-CA. Primary amyloidosis was excluded by serum/urine protein electrophoresis with serum immunofixation.

          Results

          SAVR was performed in 46 AS patients (age 70 ± 5 years, 70% men). PYP scan was performed for 32 patients, with significant PYP uptake in 3 (n = 3 of 32, 9.4%), suggestive of myocardial ATTR-CA. On histopathological examination, none of the interventricular septum biopsy specimens had amyloid deposits, whereas 33 (71.7%) native aortic valves showed amyloid deposits, of which 19 (57.6%) had transthyretin deposition suggestive of isolated valvular amyloidosis. Noninvasive markers of dual disease included low myocardial contraction fraction (median [interquartile range], 28.8% [23.8% to 39.1%] vs 15.3% [9.3% to 16.1%]; P = 0.006), deceleration time (215 [144 to 236] ms vs 88 [60 to 106] ms; P = 0.009) and global longitudinal strain (-18.7% [-21.1% to -16.9%] vs -14.2% [-17.0% to -9.7%]; P = 0.030). At 1-year follow-up, 2 patients died (4.3%); 1 each in myocardial ATTR-CA negative and positive groups (3.4% vs 33.3%; P = 0.477).

          Conclusions

          Dual disease is not uncommon in India. Isolated valvular amyloidosis in severe AS is much more common.

          Central Illustration

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: found

          Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

          Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal cardiomyopathy for which several promising therapies are in development. The diagnosis is frequently delayed or missed because of the limited specificity of echocardiography and the traditional requirement for histological confirmation. It has long been recognized that technetium-labeled bone scintigraphy tracers can localize to myocardial amyloid deposits, and use of this imaging modality for the diagnosis of cardiac ATTR amyloidosis has lately been revisited. We conducted a multicenter study to ascertain the diagnostic value of bone scintigraphy in this disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Recommendations on the Echocardiographic Assessment of Aortic Valve Stenosis: A Focused Update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography.

            Echocardiography is the key tool for the diagnosis and evaluation of aortic stenosis. Because clinical decision-making is based on the echocardiographic assessment of its severity, it is essential that standards are adopted to maintain accuracy and consistency across echocardiographic laboratories. Detailed recommendations for the echocardiographic assessment of valve stenosis were published by the European Association of Echocardiography and the American Society of Echocardiography in 2009. In the meantime, numerous new studies on aortic stenosis have been published with particular new insights into the difficult subgroup of low gradient aortic stenosis making an update of recommendations necessary. The document focuses in particular on the optimization of left ventricular outflow tract assessment, low flow, low gradient aortic stenosis with preserved ejection fraction, a new classification of aortic stenosis by gradient, flow and ejection fraction, and a grading algorithm for an integrated and stepwise approach of aortic stenosis assessment in clinical practice.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Systemic amyloidosis.

              Tissue deposition of protein fibrils causes a group of rare diseases called systemic amyloidoses. This Seminar focuses on changes in their epidemiology, the current approach to diagnosis, and advances in treatment. Systemic light chain (AL) amyloidosis is the most common of these conditions, but wild-type transthyretin cardiac amyloidosis (ATTRwt) is increasingly being diagnosed. Typing of amyloid fibrils, a critical determinant of therapy, has improved with the wide availability of laser capture and mass spectrometry from fixed histological tissue sections. Specific and accurate evaluation of cardiac amyloidosis is now possible using cardiac magnetic resonance imaging and cardiac repurposing of bone scintigraphy tracers. Survival in AL amyloidosis has improved markedly as novel chemotherapy agents have become available, but challenges remain in advanced disease. Early diagnosis, a key to better outcomes, still remains elusive. Broadening the amyloid-specific therapeutic landscape to include RNA inhibitors, fibril formation stabilisers and inhibitors, and immunotherapeutic targeting of amyloid deposits holds promise to transform outcomes in systemic amyloidoses.
                Bookmark

                Author and article information

                Contributors
                @Singal_Aayush
                @bansalrags
                @AvinainderSingh
                @DorbalaSharmila
                @ProfBhargava
                @drkarthik2010
                @aiims_newdelhi
                Journal
                JACC CardioOncol
                JACC CardioOncol
                JACC: CardioOncology
                Elsevier
                2666-0873
                19 October 2021
                October 2021
                19 October 2021
                : 3
                : 4
                : 565-576
                Affiliations
                [a ]Department of Cardiology, AIIMS, New Delhi, India
                [b ]Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA
                [c ]Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA
                [d ]Department of Medicine, Henry Ford Hospital, Detroit, Michigan, USA
                [e ]Indian Council of Medical Research, New Delhi, India, and Department of Health Research (Ministry of Health and Family Welfare), Government of India, New Delhi, India
                [f ]Department of CTVS, AIIMS, New Delhi, India
                [g ]Department of Nuclear Medicine, AIIMS, New Delhi, India
                [h ]Department of Pathology, AIIMS, New Delhi, India
                Author notes
                [] Address for correspondence: Dr Sundeep Mishra, Department of Cardiology, Cardio Thoracic Sciences Center, All India Institute of Medical Sciences (AIIMS), Sri Aurobindo Marg, Ansari Nagar East, New Delhi 110029, India. drsundeepmishranic@ 123456gmail.com @aiims_newdelhi
                Article
                S2666-0873(21)00203-9
                10.1016/j.jaccao.2021.08.008
                8551518
                34746852
                9ee2da87-48ca-41af-8b9d-a808b57a67be
                © 2021 The Authors

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 15 April 2021
                : 15 August 2021
                : 18 August 2021
                Categories
                Original Research

                dual aortic stenosis transthyretin cardiac amyloidosis,severe aortic stenosis,transthyretin cardiac amyloidosis,99m-technetium pyrophosphate scan,99mtc-pyp, 99m-technetium pyrophosphate,as, aortic stenosis,al-ca, light chain cardiac amyloidosis,attr-ca, transthyretin cardiac amyloidosis,emb, endomyocardial biopsy,gls, global longitudinal strain,ihc, immunohistochemistry,lflg as, low-flow, low-gradient aortic stenosis,savr, surgical aortic valve replacement,tavr, transcatheter aortic valve replacement,ttr, transthyretin

                Comments

                Comment on this article